Skip to contentA
Actinium Pharmaceuticals, Inc.
A
ATNMActinium Pharmaceuticals, Inc. Q1 2023 · 10-Q
Revenue—
Net Income-$11.04M-$11.04MN/M vs Q1 2022 EPS Diluted-$0.43-$0.43N/M vs Q1 2022 Operating Income-$11,584,000N/M Operating Cash Flow-$15,077,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Actinium Pharmaceuticals, Inc. · CIK 1388320 · Engraved from SEC EDGAR
Free Cash Flowderived-$15,153,000N/M ended Mar 31, 2023 · filed May 15, 2023 · 45 d after period end